晚期及复发性子宫内膜癌规范化辅助治疗OA

Advanced and recurrent endometrial cancer is highly heterogeneous,and treatment decisions need to be stratified based on disease status,pathological type,molecular markers,and prior treatment exposure.In recent years,with molecular classification gradually entering clinical practice,the treatment for advanced and recurrent endometrial cancer has shifted from a predominantly empirical chemotherapy approach to individualized therapy based on biological characteristics.For patients requiring systemic therapy,immunotherapy combined with chemotherapy has reshaped the first-line treatment landscape,with the most definite benefits observed in the dMMR/MSI-H population,while the optimal treatment pathway for the pMMR population remains to be further optimized.Patients with HER2-positive highly aggressive subtypes and those with ER/PR-positive,relatively slow-progressing disease can also benefit from corresponding targeted or endocrine therapies.At the same time,radiotherapy and other local treatments still have significant value in patients with local recurrence,pelvic-limited recurrence,and oligometastases.This article based on recent evidence,reviews,pre-treatment evaluation,systemic drug therapy,and local treatment strategies for advanced and recurrent endometrial cancer,aiming to provide a reference for standardized management.